The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation

Cancer Biology and Therapy

Volumn 18, Issue 7, 2017, Pages 484-491

  Kung, Che Pei ^a,b   Liu, Qin ^a   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AICAR; CDKN1A (p21); growth arrest; nutrient deprivation; p53

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; BROXURIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXYCYCLINE; ETOPOSIDE; LIPOCORTIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PRKAB2 PROTEIN; PROPIDIUM IODIDE; PROTEIN; PROTEIN P53; PUMA PROTEIN; SERINE; UNCLASSIFIED DRUG; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL FATE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CODON; CONTROLLED STUDY; ENZYME ACTIVATION; HCT 116 CELL LINE; HUMAN; HUMAN CELL; MALE; MOUSE; NCI-H1299 CELL LINE; NONHUMAN; NUTRIENT DEPRIVATION; NUTRITIONAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; ENERGY METABOLISM; FIBROBLAST; GENETICS; METABOLISM; MUTATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FIBROBLASTS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85020751745     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2017.1323595     Document Type: Article

References (28)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Na Rev Cancer 2009; 9:749-58; PMID:19776744; https://doi.org/10.1038/nrc2723
2. Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ 2006; 13:916-20; PMID:16557270; https://doi.org/10.1038/sj.cdd.4401907
3. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Na Rev Cancer 2009; 9:95-107; PMID:19165225; https://doi.org/10.1038/nrc2584
4. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66:5104-10; PMID:16707433; https://doi.org/10.1158/0008-5472.CAN-06-0180
5. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602; PMID:15550242; https://doi.org/10.1016/j.cell.2004.11.022
6. Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 2016; 30:918-30; PMID:27034505; https://doi.org/10.1101/gad.275891.115
7. Basu S, Barnoud T, Kung CP, Reiss M, Murphy ME. The African-specific S47 polymorphism of p53 alters chemosensitivity. Cell cycle 2016; 15:2557-60; PMID:27484708; https://doi.org/10.1080/15384101.2016.1215390
8. Murphy ME, Liu S, Yao S, Huo D, et al. A functionally significant SNP in TP53 and breast cancer risk in African American women. NPJ Breast Cancer 2017; 3:5; PMID:28232952; https://doi.org/:10.1038/s41523-017-0007-9
9. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-100; PMID:9891044; https://doi.org/10.1128/MCB.19.2.1092
10. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-65; PMID:12567188; https://doi.org/10.1038/ng1093
11. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011; 31:1201-13; PMID:21245379; https://doi.org/10.1128/MCB.01136-10
12. Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, George DL, Ahima RS, Murphy ME. The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Rep 2016; 14:2413-25; PMID:26947067; https://doi.org/10.1016/j.celrep.2016.02.037
13. Leu JI, Murphy ME, George DL. The p53 Codon 72 polymorphism modifies the cellular response to inflammatory challenge in the liver. J Liver 2013; 2:117; PMID:23991369; https://doi.org/10.4172/2167-0889.1000117
14. Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME. Identification of TRIML2, a Novel p53 target, that enhances p53-SUMOylation and regulates the transactivation of pro-apoptotic genes. Mol Cancer Res 2015 Feb; 13(2):250-62; PMID:25256710; https://doi.org/10.1158/1541-7786.MCR-14-0385
15. Feng Z, Zhang C, Kang HJ, Sun Y, Wang H, Naqvi A, Frank AK, Rosenwaks Z, Murphy ME, Levine AJ, et al. Regulation of female reproduction by p53 and its family members. FASEB J 2011; 25:2245-55; PMID:21402718; https://doi.org/10.1096/fj.10-180166
16. Sjalander A, Birgander R, Kivela A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995; 45:144-9; PMID:7615299; https://doi.org/10.1159/000154275
17. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44:266-70; PMID:7927355; https://doi.org/10.1159/000154228
18. Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, Jorgensen T, Sandbæk A, Lauritzen T, Madsbad S, Hansen T, et al. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PloS one 2011; 6:e15813; PMID:21283750; https://doi.org/10.1371/journal.pone.0015813
19. Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, et al. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 2008; 57:3136-44; PMID:18678618; https://doi.org/10.2337/db07-1731
20. Gloria-Bottini F, Banci M, Saccucci P, Magrini A, Bottini E. Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases. Diabetes Res Clin Pract 2011; 91:e64-7; PMID:21146884; https://doi.org/10.1016/j.diabres.2010.11.031
21. Reiling E, Lyssenko V, Boer JM, Imholz S, Verschuren WM, Isomaa B, Tuomi T, Groop L, Dollé ME. Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time. Eur J Hum Genet 2012; 20:696-700; PMID:22189267; https://doi.org/10.1038/ejhg.2011.240
22. Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q, Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008; 27:2788-94; PMID:17998932; https://doi.org/10.1038/sj.onc.1210932
23. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18:283-93; PMID:15866171; https://doi.org/10.1016/j.molcel.2005.03.027
24. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52; PMID:17638885; https://doi.org/10.1158/0008-5472.CAN-06-4447
25. Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, Peng Y, Qi XB, Shou WH, Ma RL, et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 2009; 84:534-41; PMID:19344876; https://doi.org/10.1016/j.ajhg.2009.03.009
26. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6:443-50; PMID:15077116; https://doi.org/10.1038/ncb1123
27. Carvajal LA, Manfredi JJ. Another fork in the road–life or death decisions by the tumour suppressor p53. EMBO Rep 2013; 14:414-21; PMID:23588418; https://doi.org/10.1038/embor.2013.25
28. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501; PMID:9822382; https://doi.org/10.1126/science.282.5393.1497